Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1

被引:5
|
作者
Garcia-Castaneda, Maricela [1 ]
Victoria Vega, Ana [3 ]
Rodriguez, Rocio [2 ]
Guadalupe Montiel-Jaen, Maria [1 ]
Cisneros, Bulmaro [2 ]
Zarain-Herzberg, Angel [4 ]
Avila, Guillermo [1 ]
机构
[1] IPN, CINVESTAV, Dept Biochem, AP 14-740, Mexico City 07000, DF, Mexico
[2] IPN, CINVESTAV, Dept Mol Biol, AP 14-740, Mexico City, DF, Mexico
[3] Univ Nacl Autonoma Mexico, UBIMED FES Iztacala, Mexico City, DF, Mexico
[4] Univ Nacl Autonoma Mexico, Sch Med, Dept Biochem, Mexico City, DF, Mexico
来源
JOURNAL OF PHYSIOLOGY-LONDON | 2017年 / 595卷 / 13期
关键词
calcium channel; excitation-contraction coupling; skeletal muscle; SLOW CALCIUM CURRENT; SKELETAL-MUSCLE; MESSENGER-RNA; CA2+ ENTRY; DIHYDROPYRIDINE RECEPTORS; MOLECULAR-MECHANISMS; CHARGE MOVEMENT; GENE; EXPRESSION; BINDING;
D O I
10.1113/JP273948
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Oculopharyngeal muscular dystrophy (OPMD) is linked to mutations in the gene encoding poly(A)-binding protein nuclear 1 (PABPN1). OPMD mutations consist of an expansion of a tract that contains 10alanines (to 12-17). This disease courses with muscle weakness that begins in adulthood, but the underlying mechanism is unclear. In the present study, we investigated the functional effects of PABPN1 and an OPMD mutation (PABPN1-17A) using myotubes transfected with cDNAs encoding these proteins (GFP-tagged). PABPN1 stimulated myoblast fusion (100%), whereas PABPN1-17A failed to mimic this effect. Additionally, the OPMD mutation markedly altered nuclear morphology; specifically, it led to nuclei with a more convoluted and ovoid shape. Although PABPN1 and PABPN1-17A modified the expression of sarcoplasmic/endoplasmic reticulum Ca2+-ATPase and calsequestrin, the corresponding changes did not have a clear impact on [Ca2+]. Interestingly, neither L-type Ca2+ channels, nor voltage-gated sarcoplasmic reticulum (SR) Ca2+ release (VGCR) was altered by PABPN1. However, PABPN1-17A produced a selective inhibition of VGCR (50%). This effect probably arises from both lower expression of RyR1 and depletion of SR Ca2+. The latter, however, was not related to inhibition of store-operated Ca2+ entry. Both PABPN1 constructs promoted a moderated decrease in cytosolic [Ca2+], which apparently results from down-regulation of excitation-coupled Ca2+ entry. On the other hand, PABPN1-17A did not alter ECC in muscle fibres, suggesting that adult muscle is less prone to developing deleterious effects. These results demonstrate that PABPN1 proteins regulate essential processes during myotube formation and support the notion that OPMD involves disruption of myogenesis, nuclear structure and homeostasis of Ca2+.
引用
收藏
页码:4167 / 4187
页数:21
相关论文
共 50 条
  • [1] Oculopharyngeal muscular dystrophy with PABPN1 mutation in a Chinese Malaysian woman
    Goh, KJ
    Wong, KT
    Nishino, I
    Minami, N
    Nonaka, I
    NEUROMUSCULAR DISORDERS, 2005, 15 (03) : 262 - 264
  • [2] Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy
    Doki, Tsukasa
    Yamashita, Satoshi
    Wei, Fan-Yan
    Hara, Kentaro
    Yamamoto, Takahiro
    Zhang, Ziwei
    Zhang, Xiao
    Tawara, Nozomu
    Hino, Hirotake
    Uyama, Eiichiro
    Kurashige, Takashi
    Maruyama, Hirofumi
    Tomizawa, Kazuhito
    Ando, Yukio
    LABORATORY INVESTIGATION, 2019, 99 (11) : 1728 - 1740
  • [3] PABPN1 gene therapy for oculopharyngeal muscular dystrophy
    Malerba, A.
    Klein, P.
    Bachtarzi, H.
    Jarmin, S. A.
    Cordova, G.
    Ferry, A.
    Strings, V.
    Espinoza, M. Polay
    Mamchaoui, K.
    Blumen, S. C.
    St Guily, J. Lacau
    Mouly, V.
    Graham, M.
    Butler-Browne, G.
    Suhy, D. A.
    Trollet, C.
    Dickson, G.
    NATURE COMMUNICATIONS, 2017, 8
  • [4] Oculopharyngeal Muscular Dystrophy with PABPN1 mutation in two Chinese Singaporean families
    Chai, Y. H. J.
    NEUROMUSCULAR DISORDERS, 2014, 24 (9-10) : 796 - 796
  • [5] A de novo PABPN1 germline mutation in a patient with oculopharyngeal muscular dystrophy
    Gürtler, N
    Plasilova, M
    Podvinec, M
    Boesch, N
    Müller, H
    Heinimann, K
    LARYNGOSCOPE, 2006, 116 (01): : 111 - 114
  • [6] PABPN1 gene therapy for oculopharyngeal muscular dystrophy
    A. Malerba
    P. Klein
    H. Bachtarzi
    S. A. Jarmin
    G. Cordova
    A. Ferry
    V. Strings
    M. Polay Espinoza
    K. Mamchaoui
    S. C. Blumen
    J. Lacau St Guily
    V. Mouly
    M. Graham
    G. Butler-Browne
    D. A. Suhy
    C. Trollet
    G. Dickson
    Nature Communications, 8
  • [7] Mutational analysis of the PABPN1 gene in oculopharyngeal muscular dystrophy
    Plata, Cristina
    Perez, Hector
    Lopez, Humberto
    Graue Moreno, Gerardo
    Astiazaran, Mirena
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [8] Muscle-specific PABPN1 regulation in Oculopharyngeal muscular dystrophy
    Phillips, B. L.
    Apponi, L. H.
    Choo, H.
    Vest, K. E.
    Pavlath, G. K.
    Corbett, A. H.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [9] hnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy
    Fan, XP
    Messaed, C
    Dion, P
    Laganiere, J
    Brais, B
    Karpati, G
    Rouleau, GA
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2003, 30 (03) : 244 - 251
  • [10] Expression and siRNA targeting of PABPN1 as a model for oculopharyngeal muscular dystrophy
    Trollet, Capucine
    Benstead, Jane
    Foster, Helen
    Graham, Ian
    Yanez-Munoz, Rafael J.
    Antoniou, Michael
    Dickson, George
    HUMAN GENE THERAPY, 2007, 18 (10) : 986 - 986